source
- Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for DuchenneRegenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…
- Create Medicines secures $122M Series B to advance in vivo CAR-T therapiesCreate Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…